Huntington'S Disease Mechanistic Pathway represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
| Property |
Value |
| Category |
Neurodegenerative Disease Mechanism |
| Related Diseases |
Huntington's Disease, Huntington's Disease-like Syndromes |
| Causative Gene |
HTT (Huntingtin) |
| Pathological Features |
Mutant huntingtin aggregates, striatal neuron loss, cortical atrophy |
The CAG repeat expansion translates to an expanded polyglutamine (polyQ) tract in the huntingtin protein, leading to:
- Protein misfolding and aggregation
- Transcriptional dysregulation
- Mitochondrial dysfunction
- Axonal transport impairment
- Synaptic dysfunction
- Loss of normal huntingtin function
Mutant huntingtin (mHTT) disrupts gene expression through:
- Sequestration of transcription factors (REST, NCoR, p53)
- Histone acetylation defects
- DNA damage accumulation
- Altered chromatin remodeling
- Loss of neuronal gene expression
mHTT impairs mitochondrial health through:
- Decreased PGC-1α expression
- Impaired mitochondrial biogenesis
- Reduced complex I/II/III activity
- Increased reactive oxygen species (ROS)
- Altered mitochondrial dynamics (fission/fusion)
- Impaired calcium handling
flowchart TD
A[mHTT Protein] --> B[Protein Aggregation)
A --> C[Transcriptional Dysregulation)
A --> D[Mitochondrial Dysfunction)
B --> E[Proteostasis Failure] -->
C --> F[Neural Gene Silencing] -->
D --> G[Energy Failure] -->
D --> H[Oxidative Stress)
E --> I[Autophagy Impairment] -->
F --> J[Synaptic Dysfunction)
G --> K[Excitotoxicity)
H --> K
I --> L[Aggregate Accumulation] -->
J --> M[Striatal Degeneration] -->
K --> M
L --> M
- mTOR Pathway: Impaired autophagy, increased aggregation
- BDNF Signaling: Reduced trophic support, synaptic failure
- CREB Signaling: Transcriptional dysfunction
- Calcium Signaling: Excitotoxicity, mitochondrial stress
- Inflammatory Response: Neuroinflammation, glial activation
¶ Genetic and Molecular Features
| Feature |
Normal |
HD |
| CAG Repeat |
<26 |
>36 |
| PolyQ Length |
<35 Q |
>36 Q |
| Age of Onset |
N/A |
Inversely correlated with repeat |
| Brain Regions Affected |
None |
Striatum, Cortex, Thalamus |
| Target |
Approach |
Status |
| HTT Gene |
Gene silencing (ASO, RNAi) |
Clinical trials |
| Mutant Protein |
Aggregation inhibitors |
Research |
| Transcriptional dysfunction |
Histone deacetylase inhibitors |
Clinical trials |
| Mitochondrial function |
PGC-1α activators |
Research |
| Neuroinflammation |
Microglial modulation |
Research |
| BDNF signaling |
BDNF mimetics |
Research |
The study of Huntington'S Disease Mechanistic Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005.
- The Huntington's Disease Collaborative Research Project. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72(6):971-983.
- Landles C, Bates GP. Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO Rep. 2004;5(10):958-963.
- Telley IA, Goldberg MW. Huntington's disease: everything in, everything out. EMBO J. 2015;34(12):1673-1674.
- Chaturvedi RK, Beal MF. Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci. 2008;1147:395-412.
- Giacomotto J, Sleigh JN, McDade K, et al. Huntington's disease: targeting CAG repeats and beyond. Nat Rev Neurol. 2022;18(7):387-402.
7.indersson MK, Stott P, Luthi-Carter R. What has CRISPR done for Huntington's disease? Nat Rev Neurol. 2021;17(12):705-706.
8.ustring EJ, Miller BR, Rao HV, et al. Mitochondrial dysfunction in Huntington's disease: from molecular mechanisms to therapeutic approaches. J Clin Invest. 2021;131(5):e145789.
- Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83-98.
- Ferrer I, Goutan E, López E, et al. Brain BDNF in Huntington's disease. J Neural Transm (Vienna). 2020;127(2):151-172.
11.hdapi R, Kumar A. Role of PGC-1α in mitochondrial dysfunction in Huntington's disease. J Mol Neurosci. 2019;68(3):332-344.
- Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev. 2010;90(3):905-981.
- Kim J, Moody JP, Edler C, et al. Selective neuronal degeneration in Huntington's disease: role of huntingtin protein. Exp Neurobiol. 2021;30(5):293-305.
- TW, Raymond LA. Synaptic dysfunction in Huntington's disease: from molecules to neuro circuits. J Clin Invest. 2021;131(5):e143628.
- Bonet-Costa V, Sun A, Jin HY, et al. Identifying gene modifiers of CAG repeat instability in Huntington's disease. Nat Commun. 2022;13(1):3015.
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
12 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 34%